Anti-MIgG(Fc)-C-PBD ADC (CAT#: ADC-AA-058)

A: PBD, the cytotoxic agent in the ADC, binds to the minor groove of DNA and cross-links DNA at specific sites. This binding disrupts the DNA structure and inhibits the transcription and replication processes, leading to cell death in targeted cells.

A: Creative Biolabs recommends using this ADC primarily for preclinical research to study targeted drug delivery and the efficacy of PBD in killing cancer cells expressing mouse IgG Fc. It serves as an invaluable tool in developing more precise and effective cancer therapies.

A: Yes, the ADC can be used to study Fc receptor-mediated activities, such as opsonization and ADCC, due to its targeting of the Fc region. This makes it a useful model for understanding how antibodies engage with the immune system and trigger cellular responses.

A: Researchers can expect that the ADC will selectively target and kill cells expressing mouse IgG Fc through the action of PBD. This targeting leads to significant DNA damage within the cancer cells, offering a potent model to study the effectiveness of antibody-drug conjugates in oncology.

A: Creative Biolabs conducts rigorous quality control processes, including validation of the binding specificity, stability testing of the linker, and efficacy tests of the cytotoxic payload. These measures ensure that each batch of ADC meets high standards for research and potential therapeutic applications.

A: This ADC targets cells expressing mouse IgG Fc by utilizing an anti-mouse IgG Fc specific polyclonal antibody. This specificity allows for selective delivery of the cytotoxic PBD to cells presenting the targeted IgG subtype, enhancing the precision of cancer cell targeting in experimental models.